secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110548
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio reports Q3 net loss of $0.37/share; Phase 3 AD trial fully activated at 84 sites
--------------------------------------------------------------------------------

- Cash and equivalents $15.3M as of Sep 30, 2025; plus $9.4M in Oct offerings.
- Phase 3 early AD study (NCT06709014) fully activated; first patients completed 6-month treatment.
- Biomarker results from Phase 2/3 showed reductions in neuroinflammation and neurodegeneration markers.
- Appointed Mark Guerin as CFO; all patents transferred to new crystal form of buntanetap (IP through 2046).
- R&D expense $6.3M (up from $2.7M YoY); net loss $0.37 per share (vs $0.97).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925110548/0001104659-25-110548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925110548/anvs-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer